Skip to main content Accessibility help
×
Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-28T19:44:24.283Z Has data issue: false hasContentIssue false

Debate 47B - Is there a Role for Immunotherapy in Treatment of Cervical Cancer?

No

from Section V - Cervical Cancer

Published online by Cambridge University Press:  20 July 2023

Dennis S. Chi
Affiliation:
Memorial Sloan-Kettering Cancer Center, New York
Nisha Lakhi
Affiliation:
Richmond University Medical Center, Staten Island
Nicoletta Colombo
Affiliation:
University of Milan-Bicocca
Get access

Summary

Cervical cancer is the fourth most commonly diagnosed and one of the deadliest cancers in women worldwide. There is an urgent need for more active treatments and rationally designed targeted therapies for advanced disease. Recently, immunotherapy has been proven to be effective in several solid tumors. There are few phase I/II studies in advanced or recurrent cervical cancer patients, no quality of life analysis in the studies, limited objective responses, and no clear superiority over second-line chemotherapy, but certainly more expense. Therefore, currently there is no role of immunotherapy in treatment of cervical cancer.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Lheureux, S, et al. Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus–related cervical carcinoma. JAMA Oncol 2018;4(7):e173776.CrossRefGoogle ScholarPubMed
Chung, HC, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2019;37(17):14701478.CrossRefGoogle ScholarPubMed
Frenel, J-S, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1–positive cervical cancer: results from the phase Ib KEYNOTE-028 Trial. J Clin Oncol 2017;35(36):40354041.CrossRefGoogle ScholarPubMed
Boussios, S, et al. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: where do we stand? A literature review. Crit Rev Oncol/Hematol 2016;108:164174.CrossRefGoogle ScholarPubMed
Naumann, RW, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 Trial. J Clin Oncol 2019;37(31):28252834.CrossRefGoogle ScholarPubMed
Naumann, RW, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with recurrent /metastatic cervical cancer: results from Checkmate 358. Ann Oncol 2019;30 (Suppl. 5):v851v934.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×